The 2026 RAS Drug Development Landscape Report
The RAS therapeutic landscape is evolving across both early and late-stage development pipelines.
This Report Offers Insight Into:
- Preclinical Pipeline Trends: Track activity by disease indication, top targets, and emerging modalities shaping early-stage RAS innovation.
- Emerging Preclinical Assets: The high-potential preclinical programmes to watch in 2026.
- Clinical Stage Development: Clinical trial trends and how leading developers are positioning in an increasingly competitive space.
- Deal and Partnership Activity: The licensing agreements and collaborations driving momentum across the RAS landscape.
You May Also Be Interested In…
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
